This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Anticonvulsant agents may cause nodal and extranodal lymphoproliferative disorders, including dermatopathic lymphadenitis, atypical lymphoid proliferation, and cutaneous pseudolymphoma.¹ In most reported cases, regression follows the discontinuation of treatment with the causative drug, but in rare cases a true lymphoma may develop.^2-3 Herein, we describe the clinicopathologic features of the first case of a CD30⁺, primary, cutaneous, anaplastic large-cell lymphoma (ALCL) possibly correlated to carbamazepine administration.

Report of a Case

A 13-year-old girl experienced lipothymic episodes during her first menses. Electroencephalography findings revealed anomalous waves, and she was administered carbamazepine (Tegretol; Novartis Farma, Origgio ([Va], Italy) in increasing doses until the dose reached 600 mg daily. After 8 months of treatment, the patient was admitted to our dermatology department for an erythematous macular eruption clinically diagnosed as pityriasis rosea. The macular eruption regressed, but 1 month later she suddenly developed multiple painless reddish skin nodules that grew and ulcerated quickly (Figure 1); . . . [Full Text of this Article]

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Glatiramer Acetate-Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Madray et al.
Arch Neurol 2008;65:1378-1379.
ABSTRACT | FULL TEXT